{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-072324","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2026-06-10T20:05:35+00:00","discovered_at":"2026-06-10T20:07:00.270692+00:00","generated_at":"2026-06-10T20:13:42.780139+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Voyager shareholders approve doubling authorized shares to 245M","bullets":["Authorized capital stock increased from 125M to 245M; common stock from 120M to 240M, effective June 9, 2026.","Shareholders elected James Geraghty, Steven Hyman, and Alfred Sandrock as Class II directors until 2029.","Ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2026.","Advisory vote on executive compensation approved with 32M for, 910K against."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-072324","json":"https://secwatch.observer/filing/0001104659-26-072324.json","markdown":"https://secwatch.observer/filing/0001104659-26-072324.md","text":"https://secwatch.observer/filing/0001104659-26-072324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/0001104659-26-072324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/tm2617230d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:13:42.780139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10a02a65b658331277593de37e4b6fa732c9e423","claim":"Voyager Therapeutics, Inc.: Increased authorized capital stock from 125,000,000 to 245,000,000 shares and common stock from 120,000,000 to 240,000,000 shares (effective 2026-06-09).","evidence_excerpt":"the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 9, 2026","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/0001104659-26-072324-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-06-09"}],"fact_type":"governance_change"},{"claim_id":"439b5fad84ca6be33c7a2b25cae8e60f57951ab1","claim":"Voyager Therapeutics, Inc. shareholders approved Amendment to Fifth Amended and Restated Certificate of Incorporation to increase authorized shares of capital stock from 125,000,000 to 245,000,000 and authorized shares of common stock from 120,000,000 to 240,000,000.","evidence_excerpt":"Voyager’s stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company’s capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares of common stock. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 43,464,491 2,593,426 108,424 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/0001104659-26-072324-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"5718a2e8ee93c7ec91fb01409a2e37a1ed44876b","claim":"Voyager Therapeutics, Inc. shareholders approved Election of Class II directors.","evidence_excerpt":"Voyager’s stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until such nominee’s successor has been duly elected and qualified, subject to such nominee’s earlier death, resignation, or removal. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes James A. Geraghty 23,336,364 9,772,133 13,057,844 Steven Hyman, M.D. 30,442,488 2,666,009 13,057,844 Alfred Sandrock, M.D., Ph.D. 31,890,428 1,218,069 13,057,844","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/0001104659-26-072324-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"7ee88d789f7776f948c7fa2aaa5b301b98b3c02f","claim":"Voyager Therapeutics, Inc. shareholders approved Non-binding advisory proposal regarding compensation of named executive officers.","evidence_excerpt":"Voyager’s stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager’s named executive officers. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 32,041,373 910,087 157,037 13,057,844","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/0001104659-26-072324-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"a67a621e971957bbc05e3a41da60d332909b6503","claim":"Voyager Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.","evidence_excerpt":"Voyager’s stockholders ratified the appointment of Ernst & Young LLP as Voyager’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 45,902,883 108,561 154,897 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/0001104659-26-072324-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-12-31"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}